TABLE 2.

PML Treatment

Treatment	All, n = 79	Hematological Malignancies, n = 38	Primary Immunodeficiencies, n = 14	HIV/AIDS, n = 12	Chronic Inflammatory Diseases, n = 8	Solid Neoplasm, n = 5	Transplant Recipients, n = 2
Type of ICI, n (%)
Nivolumab	24 (30.4)	9 (23.7)	6 (42.9)	5 (41.7)	1 (12.5)	1 (20.0)	2 (100)
Pembrolizumab	53 (67.1)	28 (73.7)	8 (57.1)	7 (58.3)	7 (87.5)	3 (60)	0 (0)
Atezolizumab	2 (2.5)	1 (2.6)	0 (0)	0 (0)	0 (0)	1 (20.0)	0 (0)
ICI injections, n, median (IQ25–75)
All	3 (2–4)	3 (2–4)	3.5 (3–12.5)	2 (1.8–2.5)	2.5 (1.8–3.3)	2 (1–2)	2 (2–2)
Nivolumab	3 (2–4.3)	3 (2–3)	15 (7.5–21)	2 (1.5–2.5)	2 (2–2)	2 (2–2)	2 (2–2)
Pembrolizumab	3 (2–4)	3 (2–4.3)	3 (2–3.3)	2 (2–4)	3 (1.5–3.5)	1 (1–1.5)	—
Atezolizumab	6.5 (4.8–8.3)	3	—	—	—	10	—
Other treatments, n (%)
Mirtazapine	25 (31.7)	7 (18.4)	5 (35.7)	8 (66.7)	2 (25)	1 (20)	2 (100)
Mefloquine	6 (7.6)	2 (5.3)	2 (14.3)	0 (0)	2 (25)	0 (0)	0 (0)
IVIg	5 (6.3)	2 (5.3)	2 (14.3)	0 (0)	1 (12.5)	0 (0)	0 (0)

Abbreviation: AIDS = acquired immunodeficiency syndrome; HIV = human immunodeficiency virus; ICI = immune checkpoint inhibitor; IQ_25–75 = interquartile range.